Market Research Logo

Keratitis - Pipeline Review, H2 2015

Keratitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Keratitis - Pipeline Review, H2 2015’, provides an overview of the Keratitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Keratitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Keratitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Keratitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Keratitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Keratitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Keratitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Keratitis Overview
Therapeutics Development
Pipeline Products for Keratitis - Overview
Pipeline Products for Keratitis - Comparative Analysis
Keratitis - Therapeutics under Development by Companies
Keratitis - Therapeutics under Investigation by Universities/Institutes
Keratitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Keratitis - Products under Development by Companies
Keratitis - Products under Investigation by Universities/Institutes
Keratitis - Companies Involved in Therapeutics Development
Adamis Pharmaceuticals Corporation
Cellceutix Corporation
NanoViricides, Inc.
Peregrine Pharmaceuticals, Inc.
ReceptoPharm, Inc.
RegeneRx Biopharmaceuticals, Inc.
Sirnaomics, Inc.
The Medicines Company
Keratitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-31G - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dipyridamole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Herpecide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
moxifloxacin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGN-632 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PIM-45 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGN-259 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RPI-MN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit ATM for Herpes Keratitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STP-601 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
targocil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tigecycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Keratitis - Recent Pipeline Updates
Keratitis - Dormant Projects
Keratitis - Product Development Milestones
Featured News & Press Releases
Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials
Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial
Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259
Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Nov 04, 2013: Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Keratitis, H2 2015
Number of Products under Development for Keratitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Keratitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015
Keratitis - Pipeline by Cellceutix Corporation, H2 2015
Keratitis - Pipeline by NanoViricides, Inc., H2 2015
Keratitis - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
Keratitis - Pipeline by ReceptoPharm, Inc., H2 2015
Keratitis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2015
Keratitis - Pipeline by Sirnaomics, Inc., H2 2015
Keratitis - Pipeline by The Medicines Company, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Keratitis Therapeutics - Recent Pipeline Updates, H2 2015
Keratitis - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Keratitis, H2 2015
Number of Products under Development for Keratitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report